Anika Therapeutics Inc (NASDAQ:ANIK) — Market Cap & Net Worth
Market Cap & Net Worth: Anika Therapeutics Inc (ANIK)
Anika Therapeutics Inc (NASDAQ:ANIK) has a market capitalization of $278.50 Million ($278.50 Million) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15277 globally and #3602 in its home market, demonstrating a -0.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anika Therapeutics Inc's stock price $20.81 by its total outstanding shares 13382966 (13.38 Million). Also see Anika Therapeutics Inc (ANIK) total assets for a full breakdown of the balance sheet.
Anika Therapeutics Inc Market Cap History: 2015 to 2026
Anika Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $510.69 Million to $278.50 Million (-4.58% CAGR). Also see ANIK operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Anika Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.01% | #417 of 976 |
|
NASDAQ Composite
IXIC
|
$42.12 Trillion | 0.00% | #1479 of 3165 |
Weight: Anika Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anika Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anika Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ANIK share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.14x
Anika Therapeutics Inc's market cap is 1.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $655.23 Million | $103.38 Million | $32.55 Million | 6.34x | 20.13x |
| 2017 | $721.48 Million | $113.42 Million | $31.82 Million | 6.36x | 22.68x |
| 2018 | $449.80 Million | $105.56 Million | $18.72 Million | 4.26x | 24.03x |
| 2019 | $693.91 Million | $114.61 Million | $27.19 Million | 6.05x | 25.52x |
| 2020 | $605.71 Million | $130.46 Million | -$23.98 Million | 4.64x | N/A |
| 2021 | $479.51 Million | $147.79 Million | $4.13 Million | 3.24x | 115.99x |
| 2022 | $396.14 Million | $156.24 Million | -$14.86 Million | 2.54x | N/A |
| 2023 | $303.26 Million | $120.79 Million | -$82.67 Million | 2.51x | N/A |
| 2024 | $220.28 Million | $119.91 Million | -$56.38 Million | 1.84x | N/A |
| 2025 | $128.61 Million | $112.82 Million | -$10.88 Million | 1.14x | N/A |
Competitor Companies of ANIK by Market Capitalization
Companies near Anika Therapeutics Inc in the global market cap rankings as of September 20, 2026. Review Anika Therapeutics Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Anika Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Anika Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Anika Therapeutics Inc's market cap moved from $510.69 Million to $ 278.50 Million, with a yearly change of -4.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $278.50 Million | +116.55% |
| 2025 | $128.61 Million | -41.62% |
| 2024 | $220.28 Million | -27.36% |
| 2023 | $303.26 Million | -23.45% |
| 2022 | $396.14 Million | -17.39% |
| 2021 | $479.51 Million | -20.84% |
| 2020 | $605.71 Million | -12.71% |
| 2019 | $693.91 Million | +54.27% |
| 2018 | $449.80 Million | -37.66% |
| 2017 | $721.48 Million | +10.11% |
| 2016 | $655.23 Million | +28.30% |
| 2015 | $510.69 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Anika Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $278.50 Million USD |
| MoneyControl | $278.50 Million USD |
| MarketWatch | $278.50 Million USD |
| marketcap.company | $278.50 Million USD |
| Reuters | $278.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more